There’s a huge difference between these two examples; In the first the manufacturer tries to isolate CBD from hemp, one of the anticipated activities under the Farm Bill. The only thing done to extract is applying heat.
In the second example psychoactive d8 is manufactured by the addition of reagents in a conscious attempt to effect the making of a new chemical bond. That was not the intent of the Farm Bill.
The Farm Bill and at least California’s Cannabis Rules opened Pandora’s Box, somewhat relaxing the rules surrounding doing chemistry.
Overproduction and generous/favorable interpretation of the USDA/DEA confusion by a few hemp processors created the d8 craze resulting in widespread and sometimes questionable manufacturing practices.
This gives the authorities reason to start closing the box.
States already are closing the box for d8 sales slowly or accepting it. Federal interpretation continues to allow for anything goes isomerizations.
We literally have chemists making drugs we can’t find standards for from cbd. This albeit alarming is a revolutionary change because they’ll soon be the ones selling the standards.
You can’t write a rule on a drug you can’t identify.
The problem with the acetates is that now we are quite a bit removed from the natural/artifact/(semi)synthetic hair splitting, we are now firmly in the territory of derivatives attempting to change pharmacokinetics.
Usually, these kind of undertakings are done by Drug Discovery Companies or clandestine laboratories.
Potentially, yes. That would be part of your DEA license application. You would be making them and have a Drug Discovery partner find out if there’s more value, not some “crowd-sourced” OTC product “feedback”.